Century Therapeutics, Inc. (IPSC): Total Assets

Annual figures by period end, from SEC filings.

$223.70M
As of 2025-12-31
$287.01M
As of 2026-06-30
-22.8%
3-year compound annual growth
+15.9%
5-year compound annual growth
$486.54M2020-12-31: $106.78M2021-12-31: $437.38M2022-12-31: $486.54M2023-12-31: $360.69M2024-12-31: $353.22M2025-12-31: $223.70M$223.70M
2020-12-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$223.70M-36.7%2026-03-12, Balance as of period end
2024-12-31$353.22M-2.1%2026-03-12, Balance as of period end
2023-12-31$360.69M-25.9%2025-03-19, Balance as of period end
2022-12-31$486.54M+11.2%2024-03-14, Balance as of period end
2021-12-31$437.38M+309.6%2023-03-16, Balance as of period end
2020-12-31$106.78Mn/a2022-03-17, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
Century Therapeutics, Inc. (IPSC)2025-12-31$223.70M-36.7%
ImmunityBio, Inc. (IBRX)2025-12-31$501.90M+31.1%
Agenus Inc (AGEN)2025-12-31$226.80M+0.2%
Sutro Biopharma, Inc. (STRO)2025-12-31$173.83M-55.1%
Atara Biotherapeutics, Inc. (ATRA)2025-12-31$20.23M-81.5%
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31$448.66M+2.3%
Beam Therapeutics Inc. (BEAM)2025-12-31$1.48B+34.2%
4D Molecular Therapeutics, Inc. (FDMT)2025-12-31$566.71M+1.1%
MeiraGTx Holdings plc (MGTX)2025-12-31$244.43M-9.4%

Compare IPSC, IBRX, AGEN, STRO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗